Metraipolis › archive › dc_301d160f56aa

Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41338056
DOI
10.1016/j.breast.2025.104664
License (as archived)
solo-consultazione
Archived
2026-11-08T06:07:34.340Z
SHA-256 of the archived text
ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75
Stable URL of this page
https://metraipolis.com/documento/dc_301d160f56aa

How to cite

Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056 — Europe PMC (en), https://europepmc.org/article/MED/41338056 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_301d160f56aa (Metraipolis archive dc_301d160f56aa, sha256 ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75)
BibTeX
@misc{dc301d160f56aa,
  title = {Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41338056},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_301d160f56aa; sha256 ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41338056. Agents can read the archived copy with the MCP tool read_document.